论文部分内容阅读
目的:探讨布地奈德对支气管哮喘患者血清炎性因子及免疫功能的影响。方法:选取支气管哮喘患者98例,按照就诊顺序将其分为观察组和对照组两组,各49例。对照组采用常规治疗,观察组在对照组的基础上加用布地奈德雾化吸入治疗,对比两组患者治疗前后血清炎性因子和免疫功能指标的变化。结果:两组患者治疗后的血清白介素-6、8、17(IL-6、IL-8、IL-17)及肿瘤坏死因子-α(TNF-α)水平均较同组治疗前有显著降低(P<0.05),但观察组治疗后与对照组治疗后各指标相比较降低更为明显(P<0.05);观察组治疗后IgA、IgG、IgM、CD4+、CD8+和CD4+/CD8+均较同组治疗前有明显升高,且与对照组治疗后比较显著增加(P<0.05)。结论:布地奈德治疗支气管哮喘能够有效改善患者症状体征,降低血清炎性因子水平,提高患者机体免疫功能,值得临床推广和应用。
Objective: To investigate the effect of budesonide on serum inflammatory factors and immune function in patients with bronchial asthma. Methods: A total of 98 patients with bronchial asthma were selected and divided into observation group and control group according to the order of treatment, with 49 cases in each group. The control group was treated with conventional therapy. The observation group was treated with inhaled budesonide inhalation on the basis of the control group. The changes of serum inflammatory factors and immune function before and after treatment were compared between the two groups. Results: The levels of serum interleukin-6, 8, 17 (IL-6, IL-8, IL-17) and tumor necrosis factor-α (TNF-α) in both groups were significantly lower than those before treatment (P <0.05), but the levels of IgA, IgG, IgM, CD4 +, CD8 + and CD4 + / CD8 in the observation group were significantly lower than those in the control group after treatment (P <0.05) Group before treatment was significantly higher, and compared with the control group after treatment was significantly increased (P <0.05). Conclusion: Budesonide treatment of bronchial asthma can effectively improve the symptoms and signs of patients, reduce serum levels of inflammatory cytokines and improve immune function in patients, it is worthy of clinical promotion and application.